Dina Ben‐Yehuda

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · New England Journal of Medicine · 2005 · 2.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

A. Keith Stewart, S. Vincent Rajkumar, Meletios Α. Dimopoulos et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Carol Moreno, Richard Greil, Fatih Demırkan et al. · The Lancet Oncology · 2018 · 548 citations

Medicine, Oncology, Pharmacology +13

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Paul G. Richardson, Pieter Sonneveld, Michael Schuster et al. · Blood · 2007 · 511 citations · Full text

Medicine, Hematology, Oncology +11